|
 We are a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer. We have built our product candidate portfolio through internal discovery. We are advancing our product candidates through in-house research and development efforts. In addition, strategic collaborations with leading pharmaceutical and biopharmaceutical companies have contributed to our portfolio of product candidates. We believe the quality and breadth of our product candidate pipeline, platform technology, scientific team and strategic collaborations are unprecedented for a company of our size in this industry.
We are advancing several proprietary product candidates. Our lead product candidate, TTP488, is a novel, orally bioavailable compound that is being developed as a potential treatment for Alzheimer’s disease. TTP488 reduces Aβ deposition in the brain and improves performance in the Morris Water Maze relative to controls in a model of AD. We believe the compound has potential benefits beyond purely symptomatic effects and may be useful as a disease-modifying agent. This molecule has been licensed to Pfizer for worldwide development and commercialization. We are also developing a large molecule compound, TTP4000 a RAGE ligand binder, for the potential treatment of Alzheimer’s.
In addition to TTP488 and TTP4000, we have TTP399 a glucokinase activator, TTP607 an aurora kinase inhibitor, TTP435 an AgRP inhibitor, TTP054 the first orally available GLP1R agonist, HPP404 a histamine H3 receptor antagonist and TTP814 a PTP1B inhibitor in clinical development followed by several preclinical products that are being advanced internally. 
We have developed a proprietary drug discovery engine, TTP Translational Technology®, that we use to discover and develop novel therapeutics for major diseases. All of the drug candidates in our pipeline have been discovered using this technology. TTP Translational Technology® is a highly automated and fully integrated drug discovery process, which translates genomic and proteomic data into safe and effective small molecule therapeutics in high throughput fashion, bypassing most of the classical requirements and bottlenecks in drug discovery. We have used our technology to discover and develop drugs for our own internal pipeline and in research collaborations with pharmaceutical and biotechnology companies. The technology has delivered clinical drug candidates against a wide range of biological targets including protein-protein interactions, receptor modulators, and enzyme inhibitors.
A key element of our strategy is to establish strategic collaborations with leading pharmaceutical and biopharmaceutical companies. We have entered into collaborations with Pfizer, Novo Nordisk A/S, Merck, Cephalon, Inc. Boehringer Ingelheim and SIGA Technologies, Inc. to discover and develop small molecule therapeutics to treat human diseases. We believe that our strategic collaborations will enable us to leverage and expand our internal discovery and development capabilities and diversify risk across our pipeline.
|